Ascites is one of the complications of liver diseases and is characterised by collection of fluid in the abdomen that causes swelling. More than 25 ml of fluid may accumulate in the peritoneal cavity. The disease can be caused by portal hypertension and low level of albumin protein in the blood. Hepatitis C or B infection, abdominal cancer, pancreatitis, congestive heart failure, portal vein thrombosis, and chronic alcohol abuse are the risk factors associated with ascites. Ascites can be symptomatized by bloating, sudden weight gain, abdominal pain, diminished appetite, and distended abdomen. BioVie Inc. is in the process of developing terlipressin as a vasopressin receptor agonist for the treatment of ascites. PharmaIN Corporation is in the process of developing PHIN-103 for the treatment of ascites. Some of the companies having the pipeline of ascites include PharmaIN Corporation, BioVie Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.